Literature DB >> 18233989

Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.

C Castellares1, P Barreiro, L Martín-Carbonero, P Labarga, M E Vispo, R Casado, L Galindo, P García-Gascó, J García-Samaniego, V Soriano.   

Abstract

Liver disease is frequently seen in HIV+ patients as a result of coinfection with hepatitis B (HBV) or C (HCV) viruses, alcohol abuse and/or exposure to hepatotoxic drugs. The aim of this study was to assess the prevalence of liver cirrhosis, its main causes and clinical presentation in HIV+ patients. Observational, cross-sectional, retrospective study of all HIV+ individuals followed at one reference HIV outpatient clinic in Madrid. Liver fibrosis was measured in all cases using transient elastometry (FibroScan). All 2168 HIV+ patients on regular follow-up (76% males, 46% injecting drug users) were successfully examined by FibroScan) between October 2004 and August 2006. Liver cirrhosis was recognized in 181 (overall prevalence, 8.3%), and the main aetiologies were HCV, 82.3%; HBV, 1.6%; dual HBV/HCV, 2.8%; and triple HBV/HCV/ hepatitis delta virus (HDV) infection, 6.6%. The prevalence of cirrhosis differed among patients with distinct chronic viral hepatitis: HCV, 19.2%; HBV, 6.1%; HBV/HCV, 41.7%; and HBV/HCV/HDV, 66.7%. In 12 patients with cirrhosis (6.7%), no definite aetiology was recognized. Overall, cirrhotics had lower mean CD4 counts than noncirrhotics (408 vs 528 cells/microL respectively; P = 0.02), despite similar proportion of subjects with undetectable viraemia on highly active antiretroviral therapy. Clinical manifestations of liver cirrhosis were: splenomegaly, 61.5%; oesophageal varices, 59.8%; ascites, 22.6%; encephalopathy, 12.1%; and variceal bleeding, 6.1%. Liver cirrhosis and hepatic decompensation events are relatively frequent in HIV+ individuals. Chronic HCV and alcohol abuse, but not chronic HBV, play a major role. Transient elastometry may allow the identification of a significant number of HIV+ individuals with asymptomatic liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18233989     DOI: 10.1111/j.1365-2893.2007.00903.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  27 in total

Review 1.  Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients.

Authors:  Gyongyi Szabo; Samir Zakhari
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.

Authors:  Valentina Li Vecchi; Maurizio Soresi; Claudia Colomba; Giovanni Mazzola; Pietro Colletti; Maurizio Mineo; Paola Di Carlo; Emanuele La Spada; Giovanni Vizzini; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

3.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

4.  The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction.

Authors:  William J Towner; Lanfang Xu; Wendy A Leyden; Michael A Horberg; Chun R Chao; Beth Tang; Daniel B Klein; Leo B Hurley; Charles P Quesenberry; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

5.  Risk and Prognosis of Acute Liver Injury Among Hospitalized Patients with Hemodynamic Instability: A Nationwide Analysis.

Authors:  Najeff Waseem; Berkeley N Limketkai; Brian Kim; Tinsay Woreta; Ahmet Gurakar; Po-Hung Chen
Journal:  Ann Hepatol       Date:  2018 January-February       Impact factor: 2.400

6.  HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis.

Authors:  Jennifer C Price; Eric C Seaberg; Sheila Badri; Mallory D Witt; Kristin D'Acunto; Chloe L Thio
Journal:  J Infect Dis       Date:  2012-01-30       Impact factor: 5.226

7.  Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV.

Authors:  Trevor A Crowell; Kelly A Gebo; Ashwin Balagopal; John A Fleishman; Allison L Agwu; Stephen A Berry
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

8.  Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.

Authors:  Manuela G Neuman; Lawrence Cohen; Samir Zakhari; Radu M Nanau; Sebastian Mueller; Michelle Schneider; Charles Parry; Romina Isip; Helmut K Seitz
Journal:  Alcohol Alcohol       Date:  2014-05-09       Impact factor: 2.826

Review 9.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

10.  Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

Authors:  Michelle DallaPiazza; Valerianna K Amorosa; Russell Localio; Jay R Kostman; Vincent Lo Re
Journal:  BMC Infect Dis       Date:  2010-05-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.